Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

NCT04053322 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

172

Enrollment

OTHER

Sponsor class

Conditions

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

Interventions

DRUG: Durvalumab
DRUG: Olaparib
DRUG: Fulvestrant

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]